La vendita allo scoperto per Howmet Aerospace dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Howmet Aerospace. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Howmet Aerospace (NYSE:HWM) Azioni, Report sulle vendite allo scoperto

HOWMET AEROSPACE INC

Howmet Aerospace

Howmet Aerospace Inc produces products that are majorly used in aerospace, commercial transportation, and industrial and other markets. The company seeks to provide its customers with solutions by offering differentiated products such as airfoils with cooling and coatings for extreme temperature applications, specially designed fasteners for lightweight composite airframe construction, reduced assembly costs, lightning strike protection, and lightweight aluminum commercial wheels. It has four reportable segments namely, Engine Products, Fastening Systems, Engineered Structures, and Forged Wheels.

Shibuya,,Tokyo,,Japan,-,March,5,2022:,Exterior,Of,The

Long Ideas

Tech

Trading Ideas

PLTR

UBER

VRSN

Le azioni dell&#39;S&amp;P 500 che stanno registrando le migliori performance dell&#39;anno. Quali sono le società in forte crescita?

I migliori performer dell&#39;S&amp;P 500: ecco le azioni che stanno volando alto

Howmet Aerospace Inc

HOWA MACHINERY LTD by HOWA MACHINERY LTD.

Howmet Aerospace Inc. $3.75 Preferred Stock

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and raises the price target from $47 to $50.

News

Price Target

Analyst Ratings

APLS

Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $50

WIIM

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky is trading lower after announcing the pricing of an upsized $160 million convertible senior notes offering.

Shares of Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company&#8217;s experimental treatments.
What Happened: Sarepta Therapeutics confirmed the death of a 51-year-old man who was part of a Phase 1 trial for a gene therapy aimed at treating limb-girdle muscular dystrophy, according <a href="https://www.biocentury.com/article/656520/third-death-from-a-sarepta-gene-therapy">to</a> BioCentury. The patient died of liver failure last month after being administered the experimental treatment.
The company, already under increased scrutiny for safety issues, had not disclosed this death in a recent corporate update.&nbsp;The update revealed the company&#8217;s plan to lay off hundreds of employees after two patients died while receiving treatment for Duchenne muscular dystrophy.
The&nbsp;Food and Drug Administration&nbsp;(FDA) is currently investigating the deaths of the two teenagers who were treated with Elevidys, Sarepta&#8217;s&nbsp;approved Duchenne muscular dystrophy gene&nbsp;therapy, which&nbsp;now comes with a black box&nbsp; warning regarding acute liver injury&nbsp;and failure.
In a statement, Sarepta acknowledged the inherent risks in clinical trial participation and expressed gratitude towards the &#8220;courageous patients and families who&nbsp;participate.&#8221; The company also stated, "While we do everything possible to ensure patient safety, there is inherent risk in clinical trial participation.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/07/46448779/inside-trumps-oval-office-crypto-push-why-did-11-republicans-suddenly-change-their-vote" target="_blank" rel="noreferrer noopener">Inside Trump&#8217;s Oval Office Crypto Push: Why Did 11 Republicans Suddenly Change Their Vote? &#8211; Benzinga</a>
Why It Matters: The recent death adds to the growing safety concerns surrounding Sarepta&#8217;s gene therapies. The company&#8217;s stock had surged in July 2025, following a&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46455874/sarepta-therapeutics-stock-is-surging-after-the-bell-whats-going-on">strategic restructuring </a>and cost-cutting measures&nbsp;aimed at focusing on high-value, high-impact programs. 
However, the FDA&#8217;s request for&nbsp;a black box warning for&nbsp;acute liver injury and failure on Elevidys, Sarepta&#8217;s approved gene therapy for Duchenne muscular dystrophy, had already&nbsp;<a href="https://www.benzinga.com/news/fda/25/07/46473418/sarepta-therapeutics-reorganization-boosts-investor-confidence">raised eyebrows</a>.
The undisclosed death of the trial participant, coupled with the ongoing FDA investigation into&nbsp;the deaths of two teenagers&nbsp;treated with Elevidys, may further impact investor confidence in the company and its gene therapies.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/07/46468497/assessing-sarepta-therapeutics-insights-from-35-financial-analysts">Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

SRPT

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

IBKR

Interactive Brokers shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Philip Gibbs upgraded Materion Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) from Sector Weight to Overweight and announced a $112 price target. Materion shares closed at $88.63 on Thursday. <a href="https://www.benzinga.com/quote/mtrn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Andrew Strelzik upgraded the rating for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Market Perform to Outperform and raised the price target from $56 to $65. Chipotle shares closed at $53.54 on Thursday. <a href="https://www.benzinga.com/quote/cmg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst John Pancari upgraded Citizens Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) from In-Line to Outperform and raised the price target from $48 to $55. Citizens Financial shares closed at $48.82 on Thursday. <a href="https://www.benzinga.com/quote/cfg/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Brady Gailey upgraded Synovus Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) from Market Perform to Outperform and raised the price target from $58 to $65. Synovus Financial shares closed at $53.85 on Thursday. <a href="https://www.benzinga.com/quote/snv/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying CMG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CMG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18073749/image-249-1024x593.png" alt="" class="wp-image-991372" style="width:601px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18073749/image-249-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18073749/image-249-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18073749/image-249-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18073749/image-249.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46465973/top-2-defensive-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

MTRN

This Chipotle Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Chardan Capital analyst Daniil Gataulin downgrades Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) from Buy to Neutral.

Downgrades

CLSD

Chardan Capital Downgrades Clearside Biomedical to Neutral

American Express shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Indigo Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INACU#NASDAQ">INACU</a>) (the "Company") announced today that, commencing on or about July 30, 2025, holders of its units sold in the Company's initial public offering may elect to separately trade the Company's ordinary shares and rights included in the units. The ordinary shares and rights that are separated will trade on the Nasdaq Global Market ("Nasdaq") under the symbols "INAC" and "INACR," respectively. No fractional rights will be issued upon separation of the units and only whole rights will trade. Those units not separated will continue to trade on Nasdaq under the symbol "INACU." Holders of units will need to have their brokers contact Continental Stock Transfer &amp; Trust Company, the Company's transfer agent, in order to separate the units into ordinary shares and rights.

INAC

INACU

Indigo Acquisition Units To Begin Split Trading As INAC And INACR On Nasdaq Beginning July 30

HOND

Terrestrial Energy And HCM II Acquisition File Draft S-4 For SPAC Merger; Plan Nasdaq Listing As 'IMSR' In H2 2025

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Morgan Stanley analyst Toni Kaplan maintains Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Equal-Weight and raises the price target from $213 to $220.

CTAS

Morgan Stanley Maintains Equal-Weight on Cintas, Raises Price Target to $220

Earnings

SCHW

Schwab Trading Revenue Increased 23% YoY

Alert confirms a reversal in early weakness in TSM
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/17205417/Screenshot-2025-07-17-at-4.49.28%E2%80%AFPM-1024x879.png" alt="" class="wp-image-16026" /></figure>
Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:11 AM on July 17th, a significant trading signal occurred for Taiwan Semiconductor (TSM) as it demonstrated a Power Inflow at a price of $243.05. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in TSM's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in TSM&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSM,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $243.05. The returns on the High price ($248.27) and Close price ($245.11) after the Power Inflow are respectively 2.1% and 0.9%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Technicals

Opinion

Signals

Taiwan Semi Stock Rises 2.1% After Key Trading Signal

The U.S. Food and Drug Administration&#8217;s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Blenrep <a href="https://www.benzinga.com/general/biotech">(belantamab mafodotin-blmf) combinations</a>.
The belantamab mafodotin combinations were <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-fda-advisory-committee-review-of-blenrep-belantamab-mafodotin-blmf-combinations-for-patients-with-relapsedrefractory-multiple-myeloma/" rel="noreferrer noopener">evaluated</a> in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
The FDA will consider the committee&#8217;s recommendation as it finalises its review on Blenrep ahead of the 23 July 2025 PDUFA date.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44873982/uk-becomes-first-country-to-authorize-blenrep-in-two-combo-regimens" rel="noreferrer noopener">UK Becomes First Country To Authorize Blenrep In Two Combo Regimens</a>
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.
GSK remains confident in the benefit/risk profile of Blenrep (belantamab mafodotin-blmf) and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple myeloma.
Ahead of the meeting, the FDA staff <a target="_blank" href="https://www.fda.gov/media/187578/download" rel="noreferrer noopener">released</a> a document highlighting key issues of high rates of ocular toxicity, including keratopathy (changes in the corneal epithelium) and visual acuity changes, and poor tolerability seen with each regimen and the resulting uncertainty regarding the appropriateness of the proposed dosages of belantamab mafodotin.
Despite differences in the belantamab mafodotin dosing regimens evaluated in DREAMM-7 and DREAMM-8, there were high rates of ocular toxicity in both trials.
Most patients experienced Keratopathy and Visual Acuity (KVA) events, including high-grade events (all grades: 92% and 93% and Grade 3-4: 77% and 78%, in DREAMM-7 and DREAMM-8, respectively).
The majority of patients (70% in DREAMM-7 and 72% in DREAMM-8) experienced recurrent ocular toxicity events (median of 3 Grade 2 or higher KVA events).
Over 50% of patients (58% in DREAMM-7 and 57% in DREAMM-8) had ongoing Grade 2 or higher KVA events at the data cut-off.
In both trials, there were high rates of dose modifications due to KVA events and recurrent KVA events. The majority of patients (76% in DREAMM-7 and 78% in DREAMM-8) had at least one dose modification due to a KVA event.
The document noted that the corneal toxicity seen with belantamab mafodotin is a unique risk to this product and is not seen with currently available therapies for multiple myeloma.
In May, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsedrefractory-multiple-myeloma/" rel="noreferrer noopener">recommended</a> the approval of Blenrep for adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.
An approval decision by the European Commission is expected in the third quarter of 2025.
In 2022,&nbsp;GSK withdrew&nbsp;the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial,&nbsp;which did not meet the requirements of the FDA&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">Accelerated Approval regulations</a>.&nbsp;
Price Action: At the last check Friday, GSK stock is trading lower by 1.86% to $35.79 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46487918/peter-thiel-backed-hadrian-raises-260-million-to-build-ai-powered-mega-factory-in-arizona" target="_blank" rel="noreferrer noopener">Peter Thiel-Backed Hadrian Raises $260 Million To Build AI-Powered Mega Factory In Arizona</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Large Cap

Health Care

Movers

General

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning

Zevra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA&#xAE; (MY-PLY-FAH) (arimoclomol) and one on OLPRUVA&#xAE; (sodium phenylbutyrate) are being presented at the 42nd Annual Meeting of the Southeastern Regional Genetics Group (SERGG), taking place July 17-19, 2025, in Asheville, North Carolina. MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA is approved in the U.S. for the treatment of certain patients with urea cycle disorders (UCDs).

ZVRA

Zevra Therapeutics To Present Three Posters On MIPLYFFA And One On OLPRUVA Annual SERGG 2025

LITM

Snow Lake Begins Drilling At U.S. And Namibia Uranium Sites Amid Surge In Nuclear Demand, Eyes Maiden Resource By Year-End

Morgan Stanley analyst Erin Wright maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $428 to $316.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Morgan Stanley Maintains Overweight on Elevance Health, Lowers Price Target to $316

Schwab Total Client Assets Increased 14% YoY

Morgan Stanley analyst Dara Mohsenian maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Equal-Weight and raises the price target from $153 to $165.

Morgan Stanley Maintains Equal-Weight on PepsiCo, Raises Price Target to $165

Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $1.07 by 6.05 percent. This is a 56.16 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $5.851 billion which beat the analyst consensus estimate of $5.651 billion by 3.54 percent. This is a 24.75 percent increase over sales of $4.690 billion the same period last year.

Comments

Howmet Aerospace

Vendite allo scoperto

Howmet Aerospace (NYSE:HWM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO